{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-023806","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.568056+00:00","generated_at":"2026-05-15T19:52:42.057884+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"confidence":"high","headline":"Zura Bio presents Phase 2 TibuSURE trial design at SSc World Congress; no data yet","bullets":["Design of Phase 2 TibuSURE trial evaluating tibulizumab (dual IL-17A/BAFF inhibition) in diffuse cutaneous systemic sclerosis accepted for poster presentation.","Trial enrolls ~80 adults, randomized 1:1 tibulizumab versus placebo for 24 weeks, then 28-week open-label extension.","Primary endpoint is change in modified Rodnan Skin Score at Week 24; topline results expected first half 2027.","No clinical efficacy or safety data will be presented; poster covers rationale and study design only."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-023806","json":"https://secwatch.observer/filing/0001104659-26-023806.json","markdown":"https://secwatch.observer/filing/0001104659-26-023806.md","text":"https://secwatch.observer/filing/0001104659-26-023806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/0001104659-26-023806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465926023806/tm268054d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:52:42.057884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}